Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 10/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CYP2A13 | Q16696 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26137532 | 0.88 | KCNH2 (0.59) | KCNH2MAPTCYP2C9ALOX15HSD17B10 | |
| SCHEMBL14228229 | 0.85 | KCNH2 (0.62) | KCNH2MAPTCYP2C9ALOX15HSD17B10 | |
| SCHEMBL26505561 | 0.84 | MAPT (0.51) | KCNH2MAPTCYP2C9ALOX15HSD17B10 | |
| SCHEMBL14200340 | 0.83 | ALDH1A1 (0.46) | MEN1KMT2AALDH1A1LMNATSHR | |
| SCHEMBL19121847 | 0.82 | KCNH2 (0.62) | KCNH2MAPTCYP2C9ALOX15HSD17B10 | |
| SCHEMBL13091284 | 0.81 | KCNH2 (0.57) | KCNH2MAPTCYP2C9ALOX15HSD17B10 | |
| SCHEMBL12545827 | 0.81 | KCNH2 (0.61) | KCNH2CYP2C9ALOX15HSD17B10CYP2A13 | |
| SCHEMBL4111089 | 0.80 | CYP2A13 (0.63) | KCNH2MAPTCYP2C9ALOX15HSD17B10 | |
| SCHEMBL4547887 | 0.76 | HRH3 (0.65) | KCNH2MAPTALOX15ALDH1A1LMNA | |
| SCHEMBL23612471 | 0.75 | HTR1D (0.60) | KCNH2MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778874-B2 | Glycopeptide antibiotic monomer derivatives | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2014-07-15 | — | — | US | disclosed |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | SHIONOGI & CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | CSGALNACT1, MON2, NR2C2 | KCNH2 2677/4885MAPT 4669/4885CYP2C9 1607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.